Modulation of the intestinal microbiota as a means of primary and secondary prevention of cardiovascular catastrophes
https://doi.org/10.51793/OS.2023.26.10.009
Abstract
Background. Cardiovascular diseases associated with dyslipidemia are the leading causes of mortality and disability of the population. The peculiarities of drug therapy of hypercholesterolemia dictate the need to take into account the individual characteristics of patients, among whom persons with comorbid conditions predominate, taking a large number of drugs prescribed by narrow specialists and having a risk of side effects from treatment. Unfavorable comorbidity is a combination of dyslipidemia with chronic constipation and cystitis, especially in patients in the pre and postmenopausal period.
Results. According to recent data, this comorbidity is very unfavorable in terms of increasing the risk of adverse cardiovascular events in patients. Of course, in such patients, in addition to correcting cholesterol indicators, a parallel safe correction of comorbid conditions associated with an increased risk of cardiovascular catastrophes, in particular, constipation, bloating, recurrent cystitis, is also required. As the data of recent literature show, this problem is partially solved by modulating the intestinal microbiota. The article provides an overview of research results and approaches to complex therapy for such patients.
Conclusion. The line of nutraceuticals available on the Russian pharmaceutical market, which are a combination of probiotics and a number of synergistic components with proven effectiveness, allows, due to the modulation of the intestinal microbiota, to successfully and safely relieve patients from conditions accompanied by a high risk of the formation and progression of cardiovascular diseases and can be used as a tool for primary and secondary prevention of cardiovascular catastrophes.
About the Author
V. A. Akhmedov
Federal State Budgetary Educational Institution of Higher Education Omsk State Medical University oof the Ministry of Health of the Russian Federation
Россия
Россия
Vadim A. Akhmedov, Dr. of Sci. (Med.) Professor, Head of the Department of Medical Rehabilitation of Additional Professional Education
5 Petr Nekrasov str., Omsk, 644037
References
1. Lei Y., Xu M., Huang N., et al. Meta-analysis of the effect of probiotics or synbiotics on the risk factors in patients with coronary artery disease. Front Cardiovasc Med. 2023; 10: 1154888.
2. Gaus O. V., Livzan M. A. Gut microbiota modulation as a leading factor in the pathogenesis of the IBS phenotypes. RMJ. 2023; 5: 12-19. (In Russ.)
3. Livzan M. A., Gaus O. V., Lisovsky M. A. Diverticular disease: gut microbiota in the clinician’s practice. RMJ. 2023; 1: 20-26. (In Russ.)
4. Alcazar C. G., Paes V.M., Shao Y., et al. The association between early-life gut microbiota and childhood respiratory diseases: a systematic review. Lancet Microbe. 202; 3 (11): e867-e880.
5. Elkafas H., Walls M., Al-Hendy A., et al Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders. Front Cell Infect Microbiol. 2022; 12: 1059825.
6. Srivastava S., Dubey A. K., Madaan R., et al. Emergence of nutrigenomics and dietary components as a complementary therapy in cancer prevention. Environ Sci Pollut Res Int. 2022; 29 (60): 89853-89873.
7. Dai Y., Quan J., Xiong L., et al. Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis. Ren Fail. 2022; 44 (1): 862-880.
8. Fiocchi A., Cabana M. D., Mennini M. Current Use of Probiotics and Prebiotics in Allergy. J Allergy Clin Immunol Pract. 2022; 10 (9): 2219-2242.
9. Jie Z., Xia H.,. Zhong S. L., et al. The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications. 2017; 8: 845.
10. Zhai T., Wang P., Hu X., et al. Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment. Oxid Med Cell Longev. 2022; 2022: 3900835.
11. Pavlidou E., Fasoulas A., Mantzorou M., et al. Clinical Evidence on the Potential Beneficial Effects of Probiotics and Prebiotics in Cardiovascular Disease. Int J Mol Sci. 2022; 23 (24): 15898.
12. Lee J. Y., Kang C. H. Probiotics alleviate oxidative stress in H2O2-exposed hepatocytes and t-BHP-induced C57BL/6 mice. Microorganisms. 2022; 10 (2): 234.
13. Tripolt N. J., Leber B., Blattl D., et al. Short communication: Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, beta-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome – a pilot study. Journal of Dairy Science. 2013; 96: 89-95.
14. Kamo T., Akazawa H., Suzuki J. I., et al. Novel concept of a heart-gut axis in the pathophysiology of heart Failure. Korean Circulation Journal, 2017; 47: 663-669.
15. Karlsson F. H., Fak F., Nookaew I., et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Communications. 2012; 3: 1245.
16. Emoto T., Yamashita T., Kobayashi T., et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease. Heart and Vessels. 2017; 32: 39-46.
17. Din A. U., Hassan A., Zhu Y., et al. Amelioration of TMAO through probiotics and its potential role in atherosclerosis, Applied Microbiology and Biotechnology. 2019; 103: 9217-9228.
18. Taslim N. A., Yusuf M., Ambari A. M., et al. Anti-Inflammatory, Antioxidant, Metabolic and Gut Microbiota Modulation Activities of Probiotic in Cardiac Remodeling Condition: Evidence from Systematic Study and Meta-Analysis of Randomized Controlled Trials. Probiotics Antimicrob Proteins. 2023; 15 (4): 1049-1061.
19. Gromova O. A., Torshin I. Yu. Probiotic strain Bifidobacterium longum BB536 — a nutraceutical of a wide profile. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2022; 198 (2): 77-85. (In Russ.)
20. Al-Sheraji S. H., Amin I., Azlan A. et al. Effects of Bifidobacterium longum BB536 on lipid profile and histopathological changes in hypercholesterolaemic rats. Benef Microbes. 2015; 6 (5): 661–668.
21. El-Zahar K. M., Hassan M. F. Y., Al-Qaba S. F. Protective Effect of Fermented Camel Milk Containing Bifi dobacterium longum BB536 on Blood Lipid Profile in Hypercholesterolemic Rats. J Nutr Metab. 2021; 2021: 1557945.
22. Al-Sheraji S. H., Ismail A., Manap M. Y., et al. Hypocholesterolaemic effect of yoghurt containing Bifidobacterium pseudocatenulatum G4 or Bifidobacterium longum BB536. Food Chem. 2012; 135 (2): 356-361.
23. Gromova O. A., Torshin I. Yu. Chemoreactome analysis of natural and synthetic statins indicates a more favorable safety profi le of monacolin K. Experimental and Clinical Gastroenterology. 2022; 199 (3): 74-85.
24. Minamizuka T., Koshizaka M., Shoji M., et al. Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pac J Clin Nutr. 2021; 30 (3): 424-435.
25. Benjian C., Xiaodan H., Huiting P., et al. Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management. J Tradit Chin Med. 2022; 42 (2): 264-271.
26. Banach M., Catapano A. L., Cicero A. F. G., et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel. On Behalf Of The International Lipid Expert Panel Ilep.Pharmacol Res. 2022; 183: 106370.
27. Mazza A., Lenti S., Schiavon L., et al. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother. 2018; 105: 992-996.
28. Ruscica M., Pavanello C., Gandini S., et al. Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutr J. 2019; 18 (1): 13.
29. Dong Q., Chen D., Zhang Y., et al. Constipation and cardiovascular disease: A two-sample Mendelian randomization analysis. J. Front Cardiovasc Med. 2023; 10: 1080982.
30. Sumida K., Molnar M. Z., Potukuchi P. K., et al. Constipation and risk of death and cardiovascular events. Atherosclerosis. 2019; 281: 114-120.
31. Sundbøll J., Szépligeti S. K., Adelborg K., et al. Constipation and risk of cardiovascular diseases: a Danish population-based matched cohort study. BMJ Open. 2020; 10 (9): e037080.
32. Fedorin М. М., Livzan M. A., Gaus O. V. Clinical features and food preferences in persons with irritable bowel syndrome against the background of overweight and obesity. Consilium Medicum. 2022; 24 (5): 306-311. (In Russ.)
33. Takeda T., Asaoka D., Nojiri S., et al. Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial. N. Am J Gastroenterol. 2023; 118 (3): 561-568.
34. Bonfrate L., Di Palo D. M., Celano G., et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020; 50 (3): e13201.
35. Cheng J., Laitila A., Ouwehand A. C. Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review. Front Nutr. 2021; 8: 790561.
36. Magro D. O., de Oliveira L. M., Bernasconi I., et al. Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic constipation. Nutr J. 2014; 13: 75.
37. Tuck C. J., Taylor K. M., Gibson P. R., et al. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. Am J Gastroenterol. 2018; 113 (1): 124-134.
38. Li J., Yi X., Ai J. Broaden Horizons: The Advancement of Interstitial Cystitis/ Bladder Pain Syndrome. Int. J. Mol. Sci. 2022; 23: 14594.
39. Homma Y., Akiyama Y., Tomoe H., et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2020; 27: 578-589.
40. Clemens J. Q., Erickson D. R., Varela N. P., et al. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. J. Urol. 2022; 208: 34-42.
41. Watanabe T., Sadahira T., Hirakawa H., et al. Exploration of the proteindependent mechanism of Lactobacillus crispatus GAI98322 to prevent recurrent cystitis. J Infect Chemother. 2023; 29 (10): 1001-1004.
42. Minhos L. F., da Silva de Lima Gehlen A. C., Júnior F. F. B., et al. Evaluation of the Efficacy of Lactobacillus acidophilus in the Treatment of Cyclophosphamide-induced Hemorrhagic Cystitis in Wistar Rats. Curr Pharm Biotechnol. 2023; 24 (3): 438-449.
43. Pugliese D., Acampora A., Porreca A., et al. Effectiveness of a novel oral combination of D-Mannose, pomegranate extract, prebiotics and probiotics in the treatment of acute cystitis in women. Arch Ital Urol Androl. 2020; 92 (1): 34-38.
44. Karlsson M., Scherbak N., Khalaf H., et al. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-κB activity in Escherichia coli-stimulated urinary bladder cells. FEMS Immunology and Medical Microbiology. 2012; 66 (2): 147-156.
45. Murina F., Vicariotto F, Lubrano C. Efficacy of an orally administered combination of Lactobacillus paracasei LC11, cranberry and D-mannose for the prevention of uncomplicated, recurrent urinary tract infections in women. Urologia. 2021; 88 (1): 64-68.
Review
For citations:
Akhmedov V.A. Modulation of the intestinal microbiota as a means of primary and secondary prevention of cardiovascular catastrophes. Lechaschi Vrach. 2023;(10):60-65. (In Russ.) https://doi.org/10.51793/OS.2023.26.10.009
Views:
161
JATS XML
Email this article 
